ID | Title | Design | Medication | Scanner details | Results (CBD only) |
---|---|---|---|---|---|
 | fMRI: Task Based |  |  |  |  |
1a | Borgwardt, S. J. et al. 2008 | DBPC pseudo-randomized, repeated measures, within-subject design. 1-month washout | THC 10 mg or CBD 600 mg or placebo | 1.5 T Sigma (GE) | CBD deactivated the left temporal cortex and insula. These effects were not related to changes in anxiety, intoxication, sedation, and psychotic symptoms. Trend for less anxiety following CBD relative to placebo (p = 0 .06) |
1b | Bhattacharyya, S. et al. 2009 | DBPC pseudo-randomized, repeated measures, within-subject design. 1-month washout | THC 10Â mg or CBD 600Â mg or placebo | 1.5Â T Sigma (GE) | CBD induced trend in modulation of insula, mediotemporal gyrus, lingual gyrus, precuneus and precentral gyrus during encoding blocks and in hippocampus during recall blocks but did not survive threshold for less than 1 false positive |
1c | Bhattacharyya, S. et al. 2010 | DBPC pseudo-randomized, repeated measures, within-subject design. 1-month washout | THC 10 mg or CBD 600 mg or placebo | 1.5 T Sigma (GE) | CBD attenuated amygdala response while observing fearful which correlated with an anxiolytic effect (r = 0.551, p = 0.017). CBD also decrease amygdala response also correlated with reductions in galvanic skin response while and intensely fearful faces (r = 0.524; p = 0.049) Right temporal cortex, parahipcampal gyrus, insula and caudate were augmented by CBD during response inhibition task While listening to speech CBD the superior temporal cortex was augmented by CBD During visual processing the occipital lobe was augmented During verbal recall CBD was associated with a trend increase in activity in the striatum compared to placebo |
1d | Bhattacharyya, S. et al. 2012 | DBPC pseudo-randomized, repeated measures, within-subject design. 1-month washout | THC 10Â mg or CBD 600Â mg or placebo | 1.5Â T Sigma (GE) | CBD attenuated activation in the left medial prefrontal cortex and augmented activation in the right caudate, parahippocampal gyrus, insula, precentral gyrus and thalamus, relative to placebo during oddball salience processing. CBD also reduced response latencies |
1e | Bhattacharyya, S. et al. 2014 | DBPC pseudo-randomized, repeated measures, within-subject design. 1-month washout | THC 10Â mg or CBD 600Â mg or placebo | 1.5Â T Sigma (GE) | CBD increased fronto-striatal connectivity but decreased mediotemporal-prefrontal connectivity during oddball salience processing |
1f | Fusar Poli et al. 2009 | DBPC pseudo-randomized, repeated measures, within-subject design. 1-month washout | THC 10Â mg or CBD 600Â mg or placebo | 1.5Â T Sigma (GE) | CBD attenuated the BOLD signal in the amygdala and anterior and posterior cingulate cortex while subjects were processing intensely fearful faces, and its suppression of the amygdalar and anterior cingulate response was correlated with the concurrent reduction in SCR fluctionations. CBD also reduced activity compared to placebo in the posterior lobe of the cerebellum for 50% fearful face stimuli |
1Â g | Fusar-Poli, P. et al. 2010 | DBPC pseudo-randomized, repeated measures, within-subject design. 1-month washout | THC 10Â mg or CBD 600Â mg or placebo | 1.5Â T Sigma (GE) | In the placebo condition, BMS identified a model with driving inputs entering via the anterior cingulate and forward intrinsic connectivity between the amygdala and the anterior cingulate as the best fit. CBD but not D9-THC disrupted forward connectivity between these regions during the neural response to fearful faces |
1Â h | Winton-Brown, T. et al. 2011 | DBPC pseudo-randomized, repeated measures, within-subject design. 1-month washout | THC 10Â mg or CBD 600Â mg or placebo | 1.5Â T Sigma (GE) | CBD had no significant symptomatic effects in anxiety, intoxication, and positive psychotic symptoms. CBD was associated with activation in right temporal cortex during auditory processing |
2a | Wilson, R. et al. 2019 | DBRPC parallel-arm study | CHR received 600Â mg CBD or matched placebo, while HC received no treatment | GeneralElectric Signa HDx 3.0Â T MRI scanner | CBD attenuated the hyperactivity in the left insula/parietal operculum for CHR participants and was associated with overall slowing of reaction time |
2b | Davies. C 2022 | DBRPC parallel-arm study | CHR received 600 mg CBD or matched placebo, while HC received no treatment | GeneralElectric Signa HDx 3.0 T MRI scanner | Healthy controls showed a significant negative relationship between cortisol and parahippocampal activation (p = 0.023). During fear processing, increases in cortisol levels induced by social stress led to lower parahippocampal activation. This relationship was significantly different in placebo compared to healthy controls (p = 0.033) but not CBD conditions vs healthy controls (p = 0.67) |
2c | Bhattacharyya 2018 | DBRCT, parallel-arm study | CHR received 600Â mg CBD or matched placebo, while HC received no treatment | GeneralElectric Signa HDx 3.0Â T MRI scanner | In the CBD group activation was greater than in the placebo group but lower than in the control group in the right caudate during encoding and in the parahippocampal gyrus and midbrain during recall. The level of activation in the CBD group was thus intermediate to that in the other 2 groups |
2d | Davies C 2020 | DBRCT, parallel-arm study | CHR received 600Â mg CBD or matched placebo, while HC recived no treatment | GeneralElectric Signa HDx 3.0Â T MRI scanner | During fear processing, CHR participants receiving CBD showed greater activation than HC but lower activation than those who received placebo in the parahippocampal gyrus. CHR participants receiving CBD showed lower activation than HC but higher activation than those who received placebo in the striatum |
 3a | Lawn, W. et al. 2020 | DBRPC repeated measures, crossover design | 600 mg oral dose of CBD and matched placebo | 3-Tesla Siemens Prisma MRI Scanner | There was insufficient evidence to suggest that CBD altered reward-related brain activity |
 3b | Bloomfeild.M 2022 | DBRPC repeated measures, crossover design | 600 mg oral dose of CBD and matched placebo | 3-Tesla Siemens Prisma MRI Scanner | There was insufficient evidence to suggest that CBD altered brain regions associated with emotional processing or responding to emotional faces |
 | fMRI: Resting State |  |  |  |  |
3c | Michael A P Bloomfield et al 2020 | DBRPC repeated measures, crossover design | 600 mg CBD or placebo | 3-Tesla Siemens Prisma MRI Scanner | CBD increased CBF in the hippocampus (p = 0.004). There was no effect on memory task performance, but there was a significant correlation whereby greater CBD-induced increases in orbitofrontal CBF were associated with reduced reaction time on the 2-back working memory task ( r =  − 0.73, p = 0.005) |
3d | Matthew B Wall 2022 | DBRPC repeated measures, crossover design | 600Â mg CBD or placebo | 3-Tesla Siemens Prisma MRI Scanner | Compared to placebo, CBD was associated with a relative increase between areas in the posterior parietal lobes, parietooccipital sulcus, the left posterior cingulate and areas of the striatum involved in association CBD also led to decreased connectivity was found in the right hemisphere insula and lateral frontal cortex. Furthermore, CBD relatively decreased connectivity from the striatum sensorimotor seed-region and left cerebellum |
4 | Grimm, O. et al. 2018 | Subject observer- blinded, RCT Crossover | 10Â mg THC vs CBD 600Â mg vs placebo | 3-Tesla Siemens Trio | Increase in front striatal coupling during intake of 600Â mg CBD. ROI-putamen showed increased activity with three clusters in the frontal lobe |
5a | Pretzsch, C. M. et al. 2019 | DBRPC, repeated-measures, cross-over study | 600 mg CBD or placebo | 3 T GE Excite II | Primarily driven by the ASD group, with no significant change in controls, CBD significantly increased fALFF in the right fusiform gyrus (p = 0.041) and in the cerebellar vermis VI (p = 0.048). Within the ASD group only, CBD also significantly altered vermal functional connectivity with several of its subcortical (striatal) and cortical targets |
 | MRS |  |  |  |  |
5b | Pretzsch, C. M. et al. 2019 | DBRPC, repeated-measures, cross-over study | 600 mg CBD or placebo | 3 T GE Excite II | Across regions, CBD increased GABA + in controls, but decreased GABA + in ASD; the group difference in change in GABA + in the DMPFC was significant |
 | PET |  |  |  |  |
6 | Crippa J. et al. 2004 | DBRCT | 400Â mg CBD | Double-detector SOPHAs DST system | CBD was associated with an increased parahippocampal gyrus blood flow. CBD conditions also showed decreased blood flow to a mediotemporal cluster including the left amygdala-hippocampal complex, hypothalamus, and a cluster in the left posterior cingulate gyrus blood flow |